List of Excipients in API lusutrombopag
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing lusutrombopag
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| SHIONOGI INC | MULPLETA | lusutrombopag | 59630-551 | CARBOXYMETHYLCELLULOSE CALCIUM | 2031-09-29 |
| SHIONOGI INC | MULPLETA | lusutrombopag | 59630-551 | CELLULOSE, MICROCRYSTALLINE | 2031-09-29 |
| SHIONOGI INC | MULPLETA | lusutrombopag | 59630-551 | FERRIC OXIDE RED | 2031-09-29 |
| SHIONOGI INC | MULPLETA | lusutrombopag | 59630-551 | HYDROXYPROPYL CELLULOSE | 2031-09-29 |
| SHIONOGI INC | MULPLETA | lusutrombopag | 59630-551 | HYPROMELLOSE | 2031-09-29 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for lusutrombopag
Excipient focus: CARBOXYMETHYLCELLULOSE CALCIUM
lusutrombopag drug variants containing CARBOXYMETHYLCELLULOSE CALCIUM
| Company | Ingredient | NDC |
|---|---|---|
| SHIONOGI INC | lusutrombopag | 59630-551 |
| Eddingpharm (U S ) Inc | lusutrombopag | 85320-551 |
| >Company | >Ingredient | >NDC |
lusutrombopag drug variants not containing CARBOXYMETHYLCELLULOSE CALCIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CELLULOSE, MICROCRYSTALLINE
lusutrombopag drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| SHIONOGI INC | lusutrombopag | 59630-551 |
| Eddingpharm (U S ) Inc | lusutrombopag | 85320-551 |
| >Company | >Ingredient | >NDC |
lusutrombopag drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
lusutrombopag drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| SHIONOGI INC | lusutrombopag | 59630-551 |
| Eddingpharm (U S ) Inc | lusutrombopag | 85320-551 |
| >Company | >Ingredient | >NDC |
lusutrombopag drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROXYPROPYL CELLULOSE
lusutrombopag drug variants containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| SHIONOGI INC | lusutrombopag | 59630-551 |
| Eddingpharm (U S ) Inc | lusutrombopag | 85320-551 |
| >Company | >Ingredient | >NDC |
lusutrombopag drug variants not containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE
lusutrombopag drug variants containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| SHIONOGI INC | lusutrombopag | 59630-551 |
| Eddingpharm (U S ) Inc | lusutrombopag | 85320-551 |
| >Company | >Ingredient | >NDC |
lusutrombopag drug variants not containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM OXIDE
lusutrombopag drug variants containing MAGNESIUM OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| SHIONOGI INC | lusutrombopag | 59630-551 |
| Eddingpharm (U S ) Inc | lusutrombopag | 85320-551 |
| >Company | >Ingredient | >NDC |
lusutrombopag drug variants not containing MAGNESIUM OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
lusutrombopag drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| SHIONOGI INC | lusutrombopag | 59630-551 |
| Eddingpharm (U S ) Inc | lusutrombopag | 85320-551 |
| >Company | >Ingredient | >NDC |
lusutrombopag drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MANNITOL
lusutrombopag drug variants containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| SHIONOGI INC | lusutrombopag | 59630-551 |
| Eddingpharm (U S ) Inc | lusutrombopag | 85320-551 |
| >Company | >Ingredient | >NDC |
lusutrombopag drug variants not containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM LAURYL SULFATE
lusutrombopag drug variants containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| SHIONOGI INC | lusutrombopag | 59630-551 |
| Eddingpharm (U S ) Inc | lusutrombopag | 85320-551 |
| >Company | >Ingredient | >NDC |
lusutrombopag drug variants not containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
lusutrombopag drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| SHIONOGI INC | lusutrombopag | 59630-551 |
| Eddingpharm (U S ) Inc | lusutrombopag | 85320-551 |
| >Company | >Ingredient | >NDC |
lusutrombopag drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
lusutrombopag drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| SHIONOGI INC | lusutrombopag | 59630-551 |
| Eddingpharm (U S ) Inc | lusutrombopag | 85320-551 |
| >Company | >Ingredient | >NDC |
lusutrombopag drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TRIETHYL CITRATE
lusutrombopag drug variants containing TRIETHYL CITRATE
| Company | Ingredient | NDC |
|---|---|---|
| SHIONOGI INC | lusutrombopag | 59630-551 |
| Eddingpharm (U S ) Inc | lusutrombopag | 85320-551 |
| >Company | >Ingredient | >NDC |
lusutrombopag drug variants not containing TRIETHYL CITRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch